Literature DB >> 10719044

Cytogenetic genotoxicity of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1: comparison of ganciclovir, penciclovir and aciclovir.

R Thust1, M Tomicic, R Klöcking, P Wutzler, B Kaina.   

Abstract

The three anti-herpes nucleoside analogues ganciclovir, penciclovir and aciclovir were investigated as to their recombinogenic [sister chromatid exchange (SCE) inducing] and clastogenic activity in CHO cells expressing the thymidine kinase gene of HSV-1, which is a precondition of therapeutic activity of these drugs. The compounds were applied for the duration of one cell cycle and cytogenetic end-points were measured between 0 and 42 h after exposure. Although the nucleoside analogues are quite similar with respect to chemical structure, they differ basically in their genotoxic potency, aberration types induced as well as the time course of chromosomal damage. Aciclovir induced SCEs and chromosomal aberrations immediately after exposure but only in a concentration range much higher than that reached in blood plasma during anti-herpes therapy. The direct genotoxic activity is explained by the obligate chain terminating property of aciclovir upon incorporation into genomic DNA. On the other hand, genotoxic damage caused by ganciclovir and penciclovir is of the delayed type requiring at least one post-exposure cell cycle for its expression. Unlike aciclovir, ganciclovir is an extremely potent inducer of SCEs and chromosome breaks and translocations at concentrations far below those impairing the proliferative activity and triggering apoptosis of the target cells (as shown by our previous investigation). Penciclovir is essentially devoid of genotoxic activity. It induces SCEs only at cytotoxic/apoptotic concentrations, is only weakly clastogenic and induces premature chromosome condensation which appears to result from uncoupling of karyokinesis and cytokinesis. The genotoxic activity of ganciclovir is explained as due to repair processes triggered in the second post-exposure replication cycle at the sites of nucleoside analogue incorporation into genomic DNA. The findings have considerable implications with respect to the use of ganciclovir or other antiviral drugs in suicide gene therapy of malignant diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10719044     DOI: 10.1093/mutage/15.2.177

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  8 in total

1.  Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity.

Authors:  Jessica J O'Konek; Brendon Ladd; Sheryl A Flanagan; Mike M Im; Paul D Boucher; Tico S Thepsourinthone; John A Secrist; Donna S Shewach
Journal:  Mutat Res       Date:  2010-01-08       Impact factor: 2.433

2.  Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease.

Authors:  Donna N Douglas; Toshiyasu Kawahara; Banu Sis; David Bond; Karl P Fischer; D Lorne J Tyrrell; Jamie T Lewis; Norman M Kneteman
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

3.  High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment.

Authors:  Poonam Balani; Jerome Boulaire; Ying Zhao; Jieming Zeng; Jiakai Lin; Shu Wang
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

4.  Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells.

Authors:  M Pincha; G Salguero; D Wedekind; B S Sundarasetty; A Lin; N Kasahara; M H Brugman; A C Jirmo; U Modlich; R Gutzmer; G Büsche; A Ganser; R Stripecke
Journal:  Gene Ther       Date:  2011-03-17       Impact factor: 5.250

5.  Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovir.

Authors:  B Ladd; J J O'Konek; L J Ostruszka; D S Shewach
Journal:  Cancer Gene Ther       Date:  2011-08-26       Impact factor: 5.987

6.  Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy).

Authors:  William A. Denny
Journal:  J Biomed Biotechnol       Date:  2003

7.  Optimization of Thymidine Kinase-Based Safety Switch for Neural Cell Therapy.

Authors:  Manon Locatelli; Flavien Delhaes; Ophélie Cherpin; Margaret E Black; Stéphanie Carnesecchi; Olivier Preynat-Seauve; Youssef Hibaoui; Karl-Heinz Krause
Journal:  Cells       Date:  2022-01-31       Impact factor: 6.600

8.  MLH1 deficiency enhances tumor cell sensitivity to ganciclovir.

Authors:  J J O'Konek; P D Boucher; A A Iacco; T E Wilson; D S Shewach
Journal:  Cancer Gene Ther       Date:  2009-03-20       Impact factor: 5.987

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.